In the global pharmaceutical sector, the Indian CRDMO (Contract Research, Development, and Manufacturing Organization) sector is rapidly emerging as one of the most compelling growth stories. What was once a cost-arbitrage-driven outsourcing destination has transformed into a strategic partner for global innovators. Backed by structural tailwinds, strong historical capabilities, and a rapidly evolving technology base, India seems to be positioning itself as a critical node in the global pharma supply chain.
Market Growth Rapidly Outperforming Global Peers
With the Indian CRDMO market estimated at roughly USD 7 billion in 2023, the market size is expected to more than double to USD 14 billion by 2028, growing at a robust 14% CAGR. This growth significantly outpaces the global CRDMO industry, which is expected to grow at 9% CAGR over the same period.
While this shows an impressive growth trajectory, India’s share in the global CRDMO market remains relatively modest at 3-4%, with expectations to rise to around 5% by 2028. This indicates not only rapid expansion but also significant untapped potential. Importantly, the growth is broad-based across all sub-segments, ranging from early-stage research and development to clinical and commercial manufacturing, each expected to grow at healthy early-to-mid-teen rates.
Strong Moats Defending India’s CRDMO Ecosystem
India offers the lowest R&D cost globally and the second-lowest manufacturing costs among key CRDMO markets. This advantage stems not only from lower labor costs but also from decades of expertise in process optimization, efficient scale-up operations, and cost engineering.
India has the largest number of US FDA-approved facilities outside the United States, thus further reinforcing its credibility as a global manufacturing hub. The country’s strong compliance track record, evidenced by a high proportion of non-OAI (No Official Action Indicated) inspection outcomes, further strengthens its attractiveness as a reliable outsourcing destination.
Indian pharmaceutical companies have developed world-class capabilities in the process of R&D, cost optimization, and large-scale manufacturing. This expertise allows them to deliver complex molecules efficiently while maintaining high-quality standards.
Evolution: From Generics Supplier to Strategic Partner
The journey of the pharmaceutical sector in India has been shaped by government policy and innovation. The Indian Patents Act, 1970, which recognized only process patents, played a pivotal role in building India’s strength in reverse engineering and process chemistry. It helped to establish India as the “pharmacy of the world”, supplying nearly 20% of global generics medicines.
The reintroduction of product patents in 1999 and 2005, aligned with global trade agreements, marked a turning point. It improved intellectual property protection and paved the way for deeper collaboration with global pharmaceutical companies. Today, global companies adopting a “China +1” strategy are increasingly turning to India, leveraging decades of established & accumulated expertise.
Despite strong growth, Indian CRDMOs remain substantially smaller when compared to their global peers, like US CRDMOs of USD 4.4 billion average revenue, European CRDMOs: USD 3.9 billion, Chinese CRDMOs: USD 2.3 billion, and Indian CRDMOs: USD 0.4 billion. This stark disparity highlights the immense headroom for growth and consolidation. Indian companies are still in the early stages of scaling and have significant opportunities to expand their global footprints and capabilities.
India’s CRDMO ecosystem is relatively CDMO-heavy, with a stronger focus on manufacturing compared to China, which has a more CRO (research) oriented model. Unlike China, Indian players also have diverse business models, closer to US and European peers, which often have multiple revenue streams beyond CRDMO services. This positioning provides Indian companies with the flexibility to evolve into integrated service providers, offering end-to-end solutions across the drug life cycle.
Expansion into High-Growth Modalities
India’s CRDMOs are rapidly enhancing their capabilities in advanced therapeutic areas, including Biologics, cell and gene therapies, oligonucleotides, and antibody-drug conjugates (ADCs). These modalities represent the future of pharmaceutical innovation. By investing in these areas, Indian companies are aligning themselves with global pharma pipelines and strengthening their role as strategic partners.
While Indian players now match global peers in the breadth of capabilities, they still lag in depth, particularly in large-scale biologics manufacturing and advanced discovery platforms. However, this gap presents a clear opportunity for growth through investments, acquisitions, and partnerships.
The international presence of Indian CRDMOs is increasingly expanding. By setting up operations closer to global innovation hubs, they gain faster access to new technology and improved integration into the clinical supply chain. Enhanced regulatory capabilities, stronger client relationships, and this global footprint are transforming Indian companies from cost-driven manufacturers into technology-led, innovation-focused partners.
There has been a huge influx of capital expenditure, reflecting confidence in the long-term demand. Leading companies are investing heavily to expand capacities and further build in next-generation modalities. Divi’s Laboratories aims to double its capex to support custom synthesis projects. Laurus Labs is investing over INR 50 billion in fermentation capacity. Meanwhile, Sai Life Sciences and Neuland Laboratories are scaling up investments in advanced capabilities.
This capex cycle is a strong signal of a strategic pivot towards high-value services as well as preparedness to capture a larger share of global outsourcing demand.
Risks Involved in the CRDMO Sector
Despite the strong long-term growth outlook for the CRDMO industry, the sector is exposed to multiple operational, regulatory, and strategic risks that investors and companies must keep in mind. One of the key risks is client concentration and molecule dependency. Many CRDMOs earn a significant proportion of their revenues from a few global pharmaceutical clients or commercial molecules. If a client faces clinical trial failure, a regulatory rejection delays commercialization, or shifts production to another vendor, it can significantly impact revenues and profitability. Since drug development inherently carries low success rates, pipeline uncertainty remains a major risk for the industry.
Regulatory or compliance risk is another critical challenge. CRDMOs operate in a highly regulated environment and are regularly inspected and audited by agencies such as the U.S Food and Drug Administration and the European Medicines Agency. Any adverse inspection outcome, warning letter,r or import alert can damage credibility, disrupt supplies, and lead to loss of customer trust. Therefore, maintaining high compliance standards is essential.
Capital intensity is another feature that characterizes the CRDMO industry today. Most companies are undertaking large capex investments in advanced technologies such as biologics, peptides, ADCs, and cell and gene therapies. However, delays in commercialization, underutilization of new capacities, or weaker-than-expected demand can reduce return on capital (ROC) and impact financial performance.
Conclusion: India’s CRDMO Moment is here
The Indian CRDMO industry is currently standing at a pivotal inflection point. With strong cost benefits, deep scientific expertise, robust regulatory infrastructure, and expanding capabilities in next-generation modalities. India is well-positioned to play a larger role in the global pharma ecosystem.
The journey from a generic powerhouse to a strategic innovation partner has been decades in the making. Today, the convergence of the global supply chain and its realignment, rising R&D complexity, and increasing outsourcing demand are accelerating this transformation.
Although there are still difficulties to overcome, especially around scaling depth and specialized capabilities, the direction of the trajectory is clear. Indian CRDMOs move further up the value chain, strengthening global partnerships and building the foundation for long-term growth. In the years ahead, India will not just participate in the global CRDMO market; it will help define its future.